GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eagle Pharmaceuticals Inc (NAS:EGRX) » Definitions » Pretax Margin %

Eagle Pharmaceuticals (Eagle Pharmaceuticals) Pretax Margin % : 14.38% (As of Jun. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Eagle Pharmaceuticals Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Eagle Pharmaceuticals's Pre-Tax Income for the three months ended in Jun. 2023 was $9.3 Mil. Eagle Pharmaceuticals's Revenue for the three months ended in Jun. 2023 was $64.6 Mil. Therefore, Eagle Pharmaceuticals's pretax margin for the quarter that ended in Jun. 2023 was 14.38%.

The historical rank and industry rank for Eagle Pharmaceuticals's Pretax Margin % or its related term are showing as below:

EGRX' s Pretax Margin % Range Over the Past 10 Years
Min: -100.91   Med: 11.65   Max: 30.82
Current: 11.33


EGRX's Pretax Margin % is ranked better than
67.06% of 1020 companies
in the Drug Manufacturers industry
Industry Median: 4.12 vs EGRX: 11.33

Eagle Pharmaceuticals Pretax Margin % Historical Data

The historical data trend for Eagle Pharmaceuticals's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eagle Pharmaceuticals Pretax Margin % Chart

Eagle Pharmaceuticals Annual Data
Trend Sep13 Sep14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.96 11.23 12.07 -2.65 19.40

Eagle Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.92 -5.56 21.92 15.43 14.38

Competitive Comparison of Eagle Pharmaceuticals's Pretax Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Eagle Pharmaceuticals's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eagle Pharmaceuticals's Pretax Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eagle Pharmaceuticals's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Eagle Pharmaceuticals's Pretax Margin % falls into.



Eagle Pharmaceuticals Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Eagle Pharmaceuticals's Pretax Margin for the fiscal year that ended in Dec. 2022 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2022 )/Revenue (A: Dec. 2022 )
=61.433/316.61
=19.40 %

Eagle Pharmaceuticals's Pretax Margin for the quarter that ended in Jun. 2023 is calculated as

Pretax Margin=Pre-Tax Income (Q: Jun. 2023 )/Revenue (Q: Jun. 2023 )
=9.298/64.646
=14.38 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eagle Pharmaceuticals  (NAS:EGRX) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Eagle Pharmaceuticals Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Eagle Pharmaceuticals's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Eagle Pharmaceuticals (Eagle Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
50 Tice Boulevard, Suite 315, Woodcliff Lake, NJ, USA, 07677
Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development and is under review for approval by the Food and Drug Administration.
Executives
Scott Tarriff director, officer: President and CEO 28 TUDOR ROSE TERRACE, MAHWAH NJ 07430
Richard A. Edlin director C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BOULEVARD, SUITE 315, WOODCLIFF LAKE NJ 07677
Michael Shawn Moran officer: EVP, Chief Commercial Officer C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BLVD., SUITE 315, WOODCLIFF NJ 07677
Luciana Borio director C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BLVD., SUITE 315, WOODCLIFF LAKE NJ 07677
Brian Joseph Cahill officer: Chief Financial Officer C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BOULEVARD, SUITE 315, WOODCLIFF LAKE NJ 07677
Judith Ng-cashin officer: Chief Medical Officer C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BOULEVARD, SUITE 315, WOODCLIFF LAKE NJ 07677
Hudson Executive Capital Lp director C/O CADWALADER, WICKERSHAM & TAFT, LLP, 200 LIBERTY STREET, NEW YORK NY 10281
Hec Management Gp Llc director 1185 AVENUE OF THE AMERICAS, 32ND FLOOR, NEW YORK NY 10036
Jennifer K. Simpson director C/O DELCATH SYSTEMS, INC., 810 SEVENTH AVENUE, SUITE 3505, NEW YORK NY 10019
Douglas L Braunstein director HUDSON EXECUTIVE CAPITAL LP, 570 LEXINGTON AVENUE, 35TH FLOOR, NEW YORK NY 10022
Sander A Flaum director 630 PARK AVE, NEW YORK NY 10019
Pete A. Meyers officer: Chief Financial Officer C/O TETRALOGIC PHARMACEUTICALS CORP, 343 PHOENIXVILLE PIKE, MALVERN PA 19355
David Pernock director 405 EAGLEVIEW BOULEVARD, EXTON PA 19341
Proquest Investments Iv, L.p. 10 percent owner 2430 VANDERBILT BEACH ROAD, #108 - 190, NAPLES FL 34109
Steven L. Krill officer: Chief Scientific Officer C/O EAGLE PHARMCEUTICALS, INC., 50 TICE BLVD. SUITE 315, WOODCLIFF LAKE NJ 07677

Eagle Pharmaceuticals (Eagle Pharmaceuticals) Headlines

From GuruFocus